FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...
Janux Therapeutics surged on promising early data and M&A rumors in 2024, but recent clinical updates led to a sharp stock decline. Click for more on JANX.
The U.S. is drafting rules for biopharma firms investing in China that would likely maintain their ability to ink most licensing deals for Chinese drugs. Read more here.
Deals: Apollo Global Management is in negotiations to acquire Johnson & Johnson’s DePuy Synthes orthopedics business in a ...
The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...
Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results